Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Stok Raporu

Piyasa değeri: US$2.4b

Ligand Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Ligand Pharmaceuticals CEO'su Todd Davis, Dec2022 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 6.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.5% maaş ve 89.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.43% ine doğrudan sahiptir ve bu hisseler $ 10.29M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 15 yıldır.

Anahtar bilgiler

Todd Davis

İcra Kurulu Başkanı

US$6.2m

Toplam tazminat

CEO maaş yüzdesi10.5%
CEO görev süresi1.9yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi2yrs
Yönetim Kurulu ortalama görev süresi15yrs

Son yönetim güncellemeleri

Recent updates

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23
Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 30

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

CEO Tazminat Analizi

Todd Davis'un ücretlendirmesi Ligand Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

US$45m

Jun 30 2024n/an/a

US$42m

Mar 31 2024n/an/a

US$96m

Dec 31 2023US$6mUS$650k

US$54m

Sep 30 2023n/an/a

US$21m

Jun 30 2023n/an/a

US$41m

Mar 31 2023n/an/a

US$51m

Dec 31 2022US$6mUS$49k

-US$5m

Sep 30 2022n/an/a

US$23m

Jun 30 2022n/an/a

US$27m

Mar 31 2022n/an/a

US$45m

Dec 31 2021US$328kn/a

US$76m

Sep 30 2021n/an/a

US$68m

Jun 30 2021n/an/a

US$48m

Mar 31 2021n/an/a

US$39m

Dec 31 2020US$329kn/a

US$7m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$350kn/a

US$629m

Sep 30 2019n/an/a

US$594m

Jun 30 2019n/an/a

US$677m

Mar 31 2019n/an/a

US$764m

Dec 31 2018US$343kn/a

US$143m

Sep 30 2018n/an/a

US$179m

Jun 30 2018n/an/a

US$120m

Mar 31 2018n/an/a

US$53m

Dec 31 2017US$283kn/a

US$13m

Tazminat ve Piyasa: Todd 'ın toplam tazminatı ($USD 6.22M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.54M ).

Tazminat ve Kazançlar: Todd 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Todd Davis (63 yo)

1.9yrs

Görev süresi

US$6,216,518

Tazminat

Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Chromocell Therapeutics Corporation since January 2023 and its Chairman of the Board. He is Chief Exec...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Todd Davis
CEO & Director1.9yrsUS$6.22m0.43%
$ 10.3m
Octavio Espinoza
Chief Financial Officer2yrsUS$2.45m0.13%
$ 3.2m
Andrew Reardon
Chief Legal Officer & Secretary2yrsUS$2.34m0.12%
$ 2.9m
Paul Hadden
Senior Vice President of Investments & Business Developmentno dataVeri yokVeri yok
Michael Jeong
Head of Investor Relationsno dataVeri yokVeri yok
Todd Pettingill
Director of Corporate Developmentno dataVeri yokVeri yok
Keith Marschke
Senior Vice President of Biology & Scientific Affairs6.8yrsVeri yokVeri yok
Vincent Antle
Senior Vice President of Technical Operations & QA - Capitsol6.8yrsVeri yokVeri yok
Patrick Lucy
Senior VP & CBO Protein Expression Businessno dataVeri yokVeri yok
Karen Reeves
Senior VP of Investments & Head of Clinical Strategyless than a yearVeri yokVeri yok
Richard Baxter
Senior VP of Investment Operationless than a yearVeri yokVeri yok
Scott Plesha
CEO of Pelthos Therapeuticsless than a yearVeri yokVeri yok

2.0yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: LGND 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Todd Davis
CEO & Director17.7yrsUS$6.22m0.43%
$ 10.3m
John Kozarich
Independent Chairman21.7yrsUS$361.70k0.23%
$ 5.5m
John LaMattina
Independent Director13.8yrsUS$329.20k0.15%
$ 3.7m
Stephen Sabba
Independent Director16.3yrsUS$341.70k0.16%
$ 3.8m
Jason Aryeh
Independent Director18.2yrsUS$339.20k0.45%
$ 10.6m
Shalendar Bhasin
Scientific Advisorno dataVeri yokVeri yok
Jason Haas
Independent Director2.4yrsUS$346.70k0.023%
$ 538.5k
Nancy Gray
Independent Director7.3yrsUS$336.70k0.031%
$ 731.6k
Martine Zimmermann
Independent Director1.2yrsUS$467.87kVeri yok

15.0yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LGND 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15 yıldır).